Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 4 · below the Ichimoku cloud · RSI 35 · MACD below its signal
None of the 29 investors followed here reported a position in 9969.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 9969.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 29, 2026 | Zhao (Renbin)Director (Executive) | — | 150K | — |
| Jan 13, 2025 | Shi (Yigong)Director (Non-Executive) | — | 800K | — |
| Jan 13, 2025 | Zhao (Renbin)Director (Executive) | — | 800K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.5 | 3.2 | 12.2 | 2.0 | -15.9 | 2.0 | 15.0 | 4.6 | 3.6 | -17.5 | −0.6% | ||
| 2025 | -8.9 | 65.9 | -0.8 | 11.2 | 10.8 | 16.3 | 37.6 | -6.2 | 10.8 | -23.9 | 4.0 | -17.2 | +101.5% |
| 2024 | -22.8 | -3.0 | -9.9 | -0.4 | -6.7 | 11.6 | -3.5 | 7.1 | 35.3 | -1.9 | -1.7 | -6.3 | −11.6% |
| 2023 | -0.6 | -36.5 | -2.8 | 7.5 | -19.2 | -2.9 | 15.2 | -18.3 | -10.4 | 3.9 | 6.6 | 4.6 | −49.5% |
| 2022 | -25.0 | 7.7 | -1.1 | -9.8 | -4.4 | 26.9 | -17.3 | -1.4 | -27.0 | 15.2 | 15.8 | 28.4 | −10.8% |
| 2021 | -0.9 | 39.5 | -3.7 | 35.5 | -3.5 | 20.2 | -10.3 | -15.0 | -3.2 | -11.3 | 6.4 | -23.0 | +12.2% |
| 2020 | 25.8 | -2.7 | 5.5 | 2.0 | -15.3 | -20.5 | -2.0 | 29.3 | 6.6 | +19.9% |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. The company has research collaboration and license agreement with Eli Lilly and Company to develop new medicines. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Buy / hold / sell counts
No recent headlines.